Lasa Supergenerics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022
For the nine months, sales was INR 942.45 million compared to INR 859.14 million a year ago. Revenue was INR 951.18 million compared to INR 859.63 million a year ago. Net loss was INR 236.09 million compared to INR 176.52 million a year ago. Basic loss per share from continuing operations was INR 5.8 compared to INR 4.34 a year ago. Diluted loss per share from continuing operations was INR 5.8 compared to INR 4.34 a year ago.